Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: K MAC who wrote (2072)	11/5/1997 5:30:00 PM
From: Frostman	Respond to of 23519

K MAC, Right on post, I too believe VIVUS needs to respond. Here is the line-up of Vivus management. VIVUS, Inc. 545 Middlefield Road Menlo Park, California 94025 Vivus investor relations e-mail: ir@vivus.com Phone 415-325-5511 Virgil A. Place, M.D. Chairman of the Board and Chief Scientific Officer Leland F. Wilson President and Chief Executive Officer Paul C. Doherty, Ph.D. Vice President, Research Julian Gangolli Vice President, Marketing Neil Gesundheit, M.D. Vice President, Clinical and Regulatory Affairs Terry M. Nida Vice President, Europe John Richard Vice President, Corporate Development Clair W. Sater Vice President, International Development William L. Smith Vice President, Research & Development David C. Yntema Vice President, Finance and Chief Financial Officer

To: K MAC who wrote (2072)	11/5/1997 5:43:00 PM
From: Frostman	Respond to of 23519

Here is the letter I sent Vivus on 10/29/97 (VVUS close 26 that day) <<To: +RT (1626 ) From: +Frostman Wednesday, Oct 29 1997 9:45AM EST Reply #1627 of 2074 RT, I sent the following E-Mail this morning to Vivus, I would suggest anyone with an interest in the company do the same if they have something to say. Dear Vivus Management, Vivus has a great product, plenty of cash, a good business plan, a super board, solid relationships with the market makers, an incredible jump on the competition, good earnings, and an extremely clever advertising/puiblic service campaign about to unfold. VVUS does not have significant media-presence. Every time I turn around, PFE, Zona and a host of others are getting the lime-light on TV and in the press. It is almost like the media doesn't know VVUS exists: a near death-blow in this competitive landscape. I am asking as a shareholder that Vivus develop a high-priority policy that will address this missed opportunity. I'm not talking about buying ads or writing jingles. I'm simply talking about adding some element to your team that offers critical media connections and has a burn to speak the facts about Muse and the truth about ED therapy in general. I want the next TV show, national magazine story or radio interview about ED to include our proven product as well as the gonna-be and wanna-be products. This has not been the case to date and I am frustrated as a result. The competition is shaping the overall market-positioning and market-awareness of ED therapy and therefore, Muse. This simply can't be what you had in mind. There is still time to turn this around, but the window is closing.>> and closing.....

To: K MAC who wrote (2072)	11/5/1997 6:18:00 PM
From: Tunica Albuginea	Read Replies (2) \| Respond to of 23519

KMAC, Vivus decline is in part also due to market decline.Small caps are down.Certainly PFE exaggerations helped ( Niagara ad ).However IMHO this will soon turn around.FDA has already clipped the Niagara Ad. People in the know are even as we speak picking up Vivus shares from those that want to sell them cheap.In a market correction many sell and can't see around the corner. IMHO those that are not in margin should hold onto Vivus because target price by April 98 remains $ 50 and you will never be able to buy it this cheap again. Folks like Leo have been working hard to bring the stock down because there are still 9 mill !! shorted shares out there!! Let us not forget the prize.Leo and his partner-in-short-Braddy ( I like that ),will have to cover sooner or later.Their costs are higher now because of margin interest,and perhaps that is why Leo is screaming.Perhaps there are a lot of folks working with a Major Employer, who shall remain nameless, gg, ( are Leo and Braddy part of that group? gg ) who decided last April to short Vivus because of unreal expectations from Viagra.After seeing Vivus stedily climbing they are now panicking because when UK approval comes ( any day now ) the game is over.With new Vivus production soon to come, Bingo, great eps--->short squeeze. What makes this theory appealing to me is that the short crowd seems to act in Unison, like they are all run out of a small, but strong, group of people!!! gg.Well this is just theory but I have always smelled a rat right from the Barron's article when Padma Nathan " forgot ? " gg what he had just written in the New Eng Jour of Med 3 months earlier;bizarre. TA